RASSF8 antibody
- Known as:
- RASSF8 (anti-)
- Catalog number:
- orb101866
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- RASSF8 antibody
Related genes to: RASSF8 antibody
- Gene:
- RASSF8 NIH gene
- Name:
- Ras association domain family member 8
- Previous symbol:
- C12orf2
- Synonyms:
- HoJ-1
- Chromosome:
- 12p12.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-04-05
- Date modifiied:
- 2016-10-05
Related products to: RASSF8 antibody
Related articles to: RASSF8 antibody
- INTRODUCTION: Gastric cancer remains a major global health burden with high incidence and mortality. Despite therapeutic advances, long-term survival remains unsatisfactory. Reliable biomarkers to predict therapeutic efficacy and clinical outcomes are urgently needed. This study aimed to elucidate the heterogeneity of gastric cancer using an integrative bioinformatics approach that combines single-cell RNA-sequencing (scRNA-seq) and bulk RNA-seq data. METHODS: scRNA-seq datasets were obtained from the GEO database, and bulk RNA-seq data were obtained from the TCGA. Cell communication, pseudotime analysis, and cell death scoring (cuproptosis, ferroptosis, autophagy, and pyroptosis) were performed on the basis of the scRNA-seq datasets. Stemness, survival, drug sensitivity and posttranslational modification (PTM) analyses were conducted using TCGA data. RESULTS: Cancer cells were clustered into three molecular subtypes with distinct molecular characteristics, pathway activation profiles and cell death patterns. Cell-cell communication analysis revealed subtype-specific regulatory interactions, whereas pseudotime and cell death scoring demonstrated dynamic cellular states. Bulk RNA-seq revealed five cell death patterns, among which "cell death 2" and high cuproptosis scores emerged as independent risk factors for poor prognosis. Genes such as LMF1-AS1, CAMKV, ERVW-1, ACLY, GAS2L2, RGS8, and RASSF8-AS1 were differentially expressed in the high-risk group. Samples with low stemness and elevated pyroptosis showed enhanced inferred drug resistance, particularly to LBH589. Additionally, ZDHHC22 was identified as a potential protective prognostic factor, and in vitro assays suggested its association with cell death modulation in gastric cancer. CONCLUSION: This study highlights the molecular heterogeneity of gastric cancer, demonstrating how distinct cell death patterns and PTM features shape prognosis and drug sensitivity. The identified biomarkers and resistance profiles may provide valuable guidance for personalized therapeutic strategies. - Source: PubMed
Publication date: 2026/05/30
Wu JiamingChen CongDou GuangjianHuang LiyongZhu YiChen ZhihengMao QileJia JingyiWang PeterLi Jin - - Source: PubMed
Zhang LanWang Jian-HuaLiang Rong-XinHuang Shu-TingXu JingYuan Lin-JingHuang LongZhou YunYu Xing-JuanWu Shao-YunLuo Rong-ZhenYun Jing-PingJia Wei-HuaZheng Min - The clinical significance of the long non-coding RNA (lncRNA) RASSF8-AS1 was investigated in non-small cell lung cancer (NSCLC). A comparative analysis of RASSF8-AS1 expression levels was performed in 31 paired samples of tumor tissue and adjacent morphologically normal lung tissue obtained from patients with various histological subtypes of NSCLC. Significant downregulation of RASSF8-AS1 transcript levels was observed in both lung adenocarcinoma (p = 0.0094) and squamous cell carcinoma (p = 0.0005). These findings underscore the potential of RASSF8-AS1 as a molecular marker for distinguishing histological subtypes of NSCLC. Although no significant associations were found between RASSF8-AS1 expression and patient age, tumor stage, or differentiation grade, a statistically significant correlation was identified between high RASSF8-AS1 expression and reduced overall survival specifically in patients with lung adenocarcinoma (hazard ratio, HR = 6.063; p = 0.029). This suggests that lncRNA RASSF8-AS1 may serve as a potential prognostic biomarker in this subgroup. Collectively, the results indicate a possible role for RASSF8-AS1 in NSCLC pathogenesis and support its further evaluation as both a molecular target and a prognostic tool, particularly in the context of personalized therapeutic strategies for lung adenocarcinoma. - Source: PubMed
Publication date: 2026/02/10
Kovaleva O VSinyov V VRashidova M AMalashenko O SMochalnikova V VKushlinskii N EGratchev A N - The uptake of modified lipoproteins by macrophages to form foam cells is a crucial step in atherosclerosis (AS) development. N7-methylguanosine (m7G) is frequently methylated internally in eukaryotic RNA transcripts and plays a crucial role in various processes. This study aimed to investigate the m7G RNA methylation profile in AS. We employed high-throughput sequencing to analyze the m7G methylome in foam cells induced by ox-LDL, using an in vitro AS model. Then, m7G-seq, RNA-seq, bioinformatic analysis, cell biological analyses, followed by qRT-PCR were performed. Additionally, the roles of SCARB2 and RASSF8 were investigated in an in vivo AS mouse model, and cells with SCARB2/RASSF8 overexpression/knockdown. In vitro and in vivo oil red O staining confirmed the successful establishment of the atherosclerotic foam cell and mouse models. We identified 1197 m7G peaks and 430 differentially expressed mRNAs during foam cell formation. Bioinformatics analyses revealed different m7G peaks associated with the gonadotropin-releasing hormone (GnRH) signaling pathway, cytoskeleton-dependent intracellular transport, and mitochondrial organization, regulating the processes of macrophage foaminess. Moreover, 28 key differentially expressed methylated genes were identified. m7G methyltransferases (WDR4, METTL1, WBSCR22) were upregulated in the AS cell model, and m7G modification genes (SCARB2 and RASSF8) associated with pathological processes were confirmed. Immunofluorescence staining showed that RASSF8 and SCARB2 were both expressed in AS mice plaque tissues. Finally, RASSF8/SCARB2 overexpression could promote apoptosis and lipid accumulation of ox-LDL-induced RAW264.7 cells. An m7G transcriptome-wide map of AS in vitro was created, and the differentially m7G methylated genes SCARB2 and RASSF8 may be crucial in macrophage foaminess. Our findings offer novel insights into the underlying mechanisms and potential treatments for AS. - Source: PubMed
Geng TaoFeng MengweiWang KaiyanWang HuiGu TianshuHu XiaotongLi JiaoWang HualingQi ShiyuShangguan WenfengWang WeidingZhang HaoLiu TongLiang Xue - Gastric cancer (GC) is globally recognized as one of the most widespread malignant tumors. As the symptoms of patients with early GC are ambiguous, the majority of patients are given a diagnosis of advanced GC. Therefore, this necessitates the search for new biomarkers to be utilized in the early diagnosis and screening of GC. Enhancer RNA (eRNA) is a non-coding RNA in transcription by enhancers that is tumor-specific and has a critical function in cancer progression. Our research investigates new eRNAs as bio-diagnostic markers for GC. Four eRNAs with good differential expression in GC were screened by TCGA and University of California, Santa Cruz databases. Quantitative real-time PCR was utilized for testing the level of RASSF8-AS1. The diagnostic effect of RASSF8-AS1 was evaluated using the receiver operating characteristic (ROC). Functional experiments were used to detect the ability of RASSF8-AS1 to affect the metastasis and proliferation in GC cells. The expression of RASSF8-AS1 was obviously elevated in both GC tissues and serum, whereas it was decreased in the serum levels of postoperative GC patients. ROC showed that RASSF8-AS1 was more diagnostically efficient than common diagnostic biomarkers for GC and that diagnostic effectiveness could be better than combining them. The findings of in vitro experiments showed that knocking down the level of RASSF8-AS1 clearly suppressed the ability of growth and metastasis in GC cells. Studies have shown that serum RASSF8-AS1 has the potential to contribute to the progression of GC as a biomarker for diagnosis and prognostic monitoring of GC. - Source: PubMed
Li XunChen XiaojueChen BairongGu XinliangChu XiuyuShen XianjuanJu Shaoqing